[ADRD] BLDRS Developed Markets 100 ADR

Overview

Type of security: Fund

Tags: ADRs, Developed markets, Equity, ETF, ex-US, Index Based, Large-cap, Not Inversed, Regional, Unleveraged, Value

The data is delayed by 15 minutes.

 

Price: 19.92 Change: 0.02 (0.1%)
Ext. hours: Change: 0 (0%)

chart ADRD

Refresh chart

Strongest Trends Summary For ADRD

ADRD is in the long-term down -52% below S&P in 14 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: The investment seeks to provide investment results that correspond generally, before fees and expenses, to the price and yield performance of the Bank of New York Developed Markets 100 ADR Index. The fund typically invests substantially all of its assets in the securities that make up the index. It is non-diversified.

Technical Data
High 52 week25.02 Low 52 week21.72 Last close23.07 Last change-0.58%
RSI63.44 Average true range0.15 Beta0.98 Volume9.61 K
Simple moving average 20 days0.93% Simple moving average 50 days1.53% Simple moving average 200 days-0.03%
Performance Data
Performance Week-0.17% Performance Month3.97% Performance Quart1.19% Performance Half-5.93%
Performance Year2.8% Performance Year-to-date-1.26% Volatility daily0.72% Volatility weekly1.61%
Volatility monthly3.29% Volatility yearly11.4% Relative Volume65.81% Average Volume7.29 K
New High New Low
Funds Characteristics
30-day SEC yield Average market capitalization Average weighted market capitalization Forward P/E
Gross expense ratio Index dividend yield Median market cap Number of holdings
Price to Book Value Price to Earnings Total expense ratio Total net assets
Weighted market capitalization

News

2018-10-30 09:40:33 | Sanofi’s Q3 Earnings: Analysts’ Estimates

2018-10-23 09:01:23 | How Novartis’s Alcon Performed in Third Quarter

2018-10-22 14:20:02 | How Novartis’s Business Segments Performed in the Third Quarter

2018-10-11 09:00:17 | Analysts’ Estimates and Ratings for Novartis in October

2018-10-10 07:31:48 | How Novartis’s Businesses Have Been Performing

2018-10-05 14:10:02 | GW Pharmaceuticals: Recommendations and Market Capitalization

2018-10-04 07:32:36 | GlaxoSmithKline ADR’s Performance and Revenues in Q3 2018

2018-10-02 07:32:03 | How GlaxoSmithKline’s Vaccines Business Has Performed Recently

2018-08-30 07:30:22 | Novartis’s Key Developments in August

2018-08-29 07:31:30 | Novartis’s Innovative Medicines Business in Q2 2018

2018-08-15 07:30:40 | Analysts’ Recommendations for GlaxoSmithKline Stock

2018-08-13 12:40:02 | Analyzing GlaxoSmithKline’s Revenue Trends

2018-07-23 11:35:02 | Novartis’s Innovative Medicines Segment in Q2 2018

2018-05-31 12:12:43 | A Look at GlaxoSmithKline’s Valuation on May 29

2018-04-30 09:02:19 | GlaxoSmithKline’s Vaccine Business in 1Q18

2018-04-25 14:30:03 | Analysts’ Views on Sanofi, Pre-1Q18 Earnings Release

2018-04-18 09:02:07 | Novartis’s 1Q18 Estimates: Expectations for Alcon

2018-03-14 09:00:29 | What Analysts Recommend for AstraZeneca in March 2018

2018-03-02 07:33:41 | Sanofi’s Established Prescription Products in 4Q17

2018-02-09 07:31:05 | Ablynx Acquisition Strengthens SNY’s Rare Blood Disorder Platform

2018-02-07 09:59:51 | Sanofi’s $11.6 Billion Bioverativ Acquisition: Highlights

2018-02-06 07:30:14 | GSK Has Emerged as Leading Player in Over-the-Counter Market

2018-02-05 09:00:03 | GSK Is Focused on Innovative Assets in Oncology Research Pipeline

2018-02-02 09:02:32 | AstraZeneca’s 4Q17 Estimates: Segment Revenues

2018-02-02 07:31:05 | Flu Season Expected to Benefit GlaxoSmithKline’s 4Q17 Revenues

2018-01-23 10:32:56 | Novartis on the Street: Analyst Ratings and Recommendations

2018-01-15 09:02:42 | Teva Pharmaceutical Focusing on Per Product Operating Profits

2017-12-22 07:31:27 | How AstraZeneca’s Respiratory Products Performed in 3Q17

2017-09-20 09:06:40 | How Does Novartis’s Ophthalmology Portfolio Look?

2017-09-15 09:07:33 | Why New Generic Products Could Boost TEVA’s Revenue Growth

2017-09-06 07:36:39 | Performance of AstraZeneca’s Oncology Segment in 2Q17

2017-09-01 09:07:55 | Analyzing GlaxoSmithKline’s Global Pharmaceuticals Business

2017-08-17 10:37:49 | How Sanofi’s Diabetes and Cardiovascular Franchise Performed

2017-08-08 14:11:06 | Will Tobacco Troubles Really Char Staples ETFs' Safety?

2017-08-02 10:37:15 | GSK’s 2Q17 Earnings: Consumer Healthcare

2017-07-12 07:37:16 | AstraZeneca Expects Brilinta to Become a Blockbuster Therapy in 2017

2017-04-04 09:06:05 | Targeted Research and Development May Boost Novartis’s Profits

2017-03-28 10:37:37 | What Do Wall Street Analysts Expect for Novartis?

2017-02-21 09:06:39 | Sanofi Pasteur: Why Human Vaccines Matter

2017-01-16 09:07:34 | How Did Novartis Perform in 3Q16?